多西他赛联合卡铂治疗前列腺癌的远期预后及其影响因素

Long-term Prognosis of Docetaxel Combined with Carboplatin for Prostate Cancer and Its Influencing Factors

目的 探讨多西他赛联合卡铂治疗前列腺癌的远期预后及其影响因素。方法 回顾性分析2016年3月至2018年3月河南大学第一附属医院收治的145例前列腺癌患者临床资料,患者均进行多西他赛联合卡铂治疗,收集并分析患者5 a预后情况及其影响因素。结果 145例患者出院后5 a内生存占比62.07%(90/145),纳入预后良好组;死亡占比37.93%(55/145),纳入预后不良组。预后不良组患者年龄及治疗前前列腺特异抗原(PSA)水平、Gleason评分高于预后良好组,治疗前血红蛋白水平低于预后良好组,差异有统计学意义(P<0.05)。高龄及治疗前PSA高水平、Gleason高评分、血红蛋白低水平是影响多西他赛联合卡铂治疗前列腺癌的远期预后不良的独立危险因素(P<0.05)。结论 多西他赛联合卡铂治疗前列腺癌的远期预后良好,影响患者预后的因素有年龄及治疗前PSA水平、Gleason评分、血红蛋白水平等。

Objective To investigate the long-term prognosis of docetaxel combined with carboplatin for prostate cancer and its influencing factors.Methods The clinical data of 145 prostate cancer patients admitted to the First Affiliated Hospital of Henan University from March 2016 to March 2018 were retrospectively analyzed,and all of whom were treated with docetaxel combined with carboplatin.The 5 years prognosis of the patients and their influencing factors were collected and analyzed.Results Survival within 5 years after discharge was 62.07%(90/145)in 145 patients and was included in the good prognosis group,and death was 37.93%(55/145)in the poor prognosis group.The age and pre-treatment prostate-specific antigen(PSA)level and Gleason score of patients in the poor prognosis group were higher than those in the good prognosis group,and the pre-treatment hemoglobin concentration was lower than that in the good prognosis group,and the differences were statistically significant(P<0.05).Advanced age and high pre-treatment PSA levels,high Gleason score and low hemoglobin concentration were independent risk factors for poor long-term prognosis in docetaxel combined with carboplatin for prostate cancer(P<0.05).Conclusion The long-term prognosis of docetaxel combined with carboplatin for prostate cancer is good.Factors affecting the prognosis of patients include age and pre-treatment PSA level,Gleason score and hemoglobin level.